Many new therapeutic approaches show promise for improving the course of pulmonary disease in CF patients. Novel therapies target a spectrum of pathogenic mechanisms, including infection and inflammation, proteolytic enzymes, and abnormal ion transport. Furthermore, gene therapy strives to correct the phenotype in CF by delivering a gene capable of producing functional CFTR. These exciting and promising approaches offer hope that we may soon increase the longevity and quality of life of CF patients.